Equity method

Arvinas Reports Third Quarter 2023 Financial Results and Provides Corporate Update

Retrieved on: 
Tuesday, November 7, 2023
Research, Sale, Arm, Equity method, Bayer, ATM, ESMO, LRRK2, RPF, Enrollment, Greyhawk, Income tax, CTA, Prostate cancer, Exercise, Development, PROTAC, Pfizer, Clinical trial, BCL6, Neuroscience, CDK4, Breast cancer, State Administrative Expenses, ARVN, Genentech, European Society of Gynaecological Oncology, Investment, AR, Patient, Administration, Everolimus, Pharmaceutical industry, Medical imaging, Dietary supplement, Life insurance, IND, Gaius Papirius Carbo Arvina

NEW HAVEN, Conn., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today reported financial results for the third quarter ended September 30, 2023 and provided a corporate update.

Key Points: 
  • Research and Development Expenses: Research and development expenses were $85.9 million for the quarter ended September 30, 2023, as compared with $77.5 million for the quarter ended September 30, 2022.
  • General and Administrative Expenses: General and administrative expenses were $22.6 million for the quarter ended September 30, 2023, as compared with $20.0 million for the quarter ended September 30, 2022.
  • Revenues: Revenues were $34.6 million for the quarter ended September 30, 2023, as compared with $33.2 million for the quarter ended September 30, 2022.
  • Net Loss: Net loss was $64.0 million for the quarter ended September 30, 2023, as compared with $66.2 million for the quarter ended September 30, 2022.

Montage Partners Announces Greg Ogard as New Vice President

Retrieved on: 
Tuesday, September 26, 2023
Finance, Consulting, Professional Services, Other Professional Services, Asset Management, NCAA, University, Health, Equity method, 2004 NCAA Division I men's ice hockey tournament, MBA, Kellogg School, Partner, Citigroup, Northwestern University, Management

Montage Partners, a people-first private equity firm based in Scottsdale, Arizona, has announced the hiring of Greg Ogard as Vice President to lead the firm’s investment strategy in the business services, healthcare, and technology sectors.

Key Points: 
  • Montage Partners, a people-first private equity firm based in Scottsdale, Arizona, has announced the hiring of Greg Ogard as Vice President to lead the firm’s investment strategy in the business services, healthcare, and technology sectors.
  • Prior to joining Montage Partners, Greg was an Associate at Platte River Equity, a middle-market private equity firm where he was responsible for deal execution and portfolio company oversight.
  • “What attracted me to Montage Partners was the firm’s people-first approach to investing and strong reputation for adding value to founder-owned companies in the lower middle market,” said Ogard.
  • “We are thrilled to welcome Greg to the Montage Partners team,” said Rob Wolfman, co-Managing Partner at Montage Partners.

Arvinas Reports Second Quarter 2023 Financial Results and Provides Corporate Update

Retrieved on: 
Tuesday, August 8, 2023
Exercise, PROTAC, Insurance, Response evaluation criteria in solid tumors, LRRK2, SLI, Everolimus, Clinical trial, RECIST, Trae Elston, CTA, Molecule, Oncology, Research, Part, EOP, Genentech, Equity method, Sale, ARVN, Development, Neuroscience, Bayer, Quantum Leap, Patient, Investment, Enrollment, Administration, Financial toxicity, European Society of Gynaecological Oncology, Therapy, IND, LBD, AR, Pfizer, Pharmaceutical industry, Medical imaging, Dietary supplement, Life insurance, Gaius Papirius Carbo Arvina

NEW HAVEN, Conn., Aug. 08, 2023 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today reported financial results for the second quarter ended June 30, 2023 and provided a corporate update.

Key Points: 
  • We are also on track to initiate a Phase 3 trial with bavdegalutamide in the second half of the year.
  • Research and Development Expenses: Research and development expenses were $103.4 million for the quarter ended June 30, 2023, as compared with $75.3 million for the quarter ended June 30, 2022.
  • Revenues: Revenues were $54.5 million for the quarter ended June 30, 2023 as compared with $33.8 million for the quarter ended June 30, 2022.
  • Net Loss: Net loss was $66.6 million for the quarter ended June 30, 2023, as compared with $70.0 million for the quarter ended June 30, 2022.

Arvinas Reports First Quarter 2023 Financial Results and Provides Corporate Update

Retrieved on: 
Friday, May 5, 2023
Exercise, PROTAC, KRAS, Neuron, CHDI, AACR, Senior, LRRK2, HTT, Survival, Everolimus, Clinical trial, Annual Meetings of the International Monetary Fund and the World Bank Group, CTA, Molecule, Research, Part, EOP, Genentech, Equity method, CBR, Sale, ARVN, Development, Incidence, Neuroscience, State Administrative Expenses, American Association for Cancer Research, Ribociclib, Quantum Leap, RAS, Patient, Administration, Enzyme inhibitor, Annual general meeting, Therapy, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Safety, IND, AR, Conference, Food, Pfizer, Breast cancer, Pharmaceutical industry, Dietary supplement, Copper, Medical imaging, Medical device, Cryptocurrency, Bayer, Gaius Papirius Carbo Arvina

NEW HAVEN, Conn., May 05, 2023 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today reported financial results for the first quarter ended March 31, 2023 and provided a corporate update.

Key Points: 
  • “We made substantial progress throughout the first quarter across all areas of our early- and late-stage pipeline,” said John Houston, Ph.D., president and chief executive officer at Arvinas.
  • Data are expected to be presented at a medical conference in the second half of 2023.
  • Revenues: Revenues were $32.5 million for the quarter ended March 31, 2023, as compared with $26.5 million for the quarter ended March 31, 2022.
  • Net Loss: Net loss was $81.9 million for the quarter ended March 31, 2023, as compared with $63.4 million for the quarter ended March 31, 2022.

World Acceptance Corporation Reports Fiscal 2023 Fourth Quarter Results

Retrieved on: 
Thursday, May 4, 2023
Banking, Professional Services, Finance, Joint Ventures, G&A, GAAP, Equity method, HTC, Acquisition, Advertising, CECL, Growth, ASU, Video game, Risk management, Bank, Investment

G&A expenses per average open branch decreased by 1.5% when comparing the fourth quarter of fiscal 2023 to the fourth quarter fiscal 2022.

Key Points: 
  • G&A expenses per average open branch decreased by 1.5% when comparing the fourth quarter of fiscal 2023 to the fourth quarter fiscal 2022.
  • Personnel expense decreased $0.2 million, or 0.4%, during the fourth quarter of fiscal 2023 as compared to the fourth quarter of fiscal 2022.
  • Incentive expense decreased $3.5 million, or 28.0%, in the fourth quarter of fiscal 2023 compared to the fourth quarter of fiscal 2022.
  • Other expense decreased $6.7 million, or 48.9%, in the fourth quarter of fiscal 2023 compared to the fourth quarter of fiscal 2022.

Arvinas Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update

Retrieved on: 
Thursday, February 23, 2023
AR, Pfizer, Development, Equity method, Genentech, Prostate cancer, Income tax, Ribociclib, Research, Patient, ARVN, Exercise, Bayer, Administration, State Administrative Expenses, Pharmaceutical industry, Cryptocurrency, Gaius Papirius Carbo Arvina

NEW HAVEN, Conn., Feb. 23, 2023 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today reported financial results for the fourth quarter and full year ended December 31, 2022 and provided a corporate update.

Key Points: 
  • Research and Development Expenses: Research and development expenses were $315.0 million and $98.3 million for the year and quarter ended December 31, 2022, as compared with $180.4 million and $61.8 million for the year and quarter ended December 31, 2021.
  • General and Administrative Expenses: General and administrative expenses were $79.6 million and $15.1 million for the year and quarter ended December 31, 2022, as compared with $61.6 million and $18.9 million for the year and quarter ended December 31, 2021.
  • Revenue: Revenue was $131.4 million and $38.0 million for the year and quarter ended December 31, 2022 as compared with $53.6 million and $28.7 million for the year and quarter ended December 31, 2021.
  • Net Loss: Net loss was $282.5 million and $82.9 million for the year and quarter ended December 31, 2022, as compared with $191.0 million and $52.9 million for the year and quarter ended December 31, 2021.

Equilar and Equity Methods Partner to Develop Industry-Leading Pay Versus Performance Solutions

Retrieved on: 
Thursday, November 10, 2022
Legal, Software, Human Resources, Finance, Data Management, Accounting, Professional Services, Technology, Associated Press, CAP, Partnership, The Wall Street Journal, Bloomberg, Silicon, Equity, SEC, View, CNBC, The New York Times, Solution, Founder, U.S. Securities and Exchange Commission, TSR, Neo, Monte Carlo, Equity method, CEO, Pay for performance, Cryptocurrency, Casino, Financial adviser

Equilar, the leading provider of corporate leadership data solutions, today announced its partnership with Equity Methods, a leader in equity compensation solutions, to help human resources, finance and legal teams address new disclosure requirements for Pay Versus Performance.

Key Points: 
  • Equilar, the leading provider of corporate leadership data solutions, today announced its partnership with Equity Methods, a leader in equity compensation solutions, to help human resources, finance and legal teams address new disclosure requirements for Pay Versus Performance.
  • As part of the partnership, Equilar and Equity Methods have developed a Monte Carlo Simulator within the Equilar Insight platform to allow companies to model and predict various outcomes related to their executive pay and performance alignment.
  • Were excited to combine our industry-leading compensation solutions with Equity Methods state-of-the-art modeling capabilities to empower our clients as they address the new SEC Pay Versus Performance requirements.
  • Monte Carlo simulation is one of the most complicated aspects of producing the core Pay Versus Performance disclosure table, said Takis Makridis, President and CEO of Equity Methods.

Group Five Releases 2022 Results for Equity Compensation Financial Reporting Services

Retrieved on: 
Thursday, September 15, 2022
NPS, Equity method, Knowledge, Creativity, Company, Face, Net Promoter, Industry, Bain & Company, Automation, Method, CEO, Workplace, Research, UBS, Customer service, Health insurance, Management

NOVATO, Calif., Sept. 15, 2022 /PRNewswire/ -- In the Group Five Financial Reporting Benchmarking Study, corporate plan sponsors rate their loyalty and satisfaction with third-party service providers who offer financial reporting services related to equity compensation plans. In this year's study, industry-wide loyalty decreased three points compared to last year's study to a Net Promoter Score (NPS)* of 50, while overall satisfaction declined by one point to 87% favorable.** The decreases in loyalty and overall satisfaction are statistically insignificant and reflect steady levels of client satisfaction with both platform functionality and reports.

Key Points: 
  • Among equity plan administration providers, UBS received the highest loyalty and overall satisfaction rating for the third year in a row.
  • NOVATO, Calif., Sept. 15, 2022 /PRNewswire/ -- In the Group Five Financial Reporting Benchmarking Study, corporate plan sponsors rate their loyalty and satisfaction with third-party service providers who offer financial reporting services related to equity compensation plans.
  • "Among clients of financial reporting service providers, loyalty and satisfaction is driven primarily by platform functionality, reporting accuracy, and support staff expertise" said Kathy Huston, President of Group Five.
  • Group Five, an industry leader in business-to-business loyalty and satisfaction research, is best known for research in equity plan administration and shareholder services.

PEOPLES FINANCIAL CORPORATION REPORTS RESULTS FOR THE FIRST QUARTER OF 2022

Retrieved on: 
Wednesday, May 11, 2022
Joint Ventures, People's Bank of China, UMB Financial Corporation, Accounting Standards Codification, Income, U.S. Securities and Exchange Commission, Equity method, Effect, Company, Form, Conversation, Private Securities Litigation Reform Act, Investment, Error, News, Financial condition report, Result, Bank, Mission statement, Analysis, Internet, Audit committee, Failure, Total, LLP, Industry, Partnership, Time, Forward-looking statement, LIHTC, Terminology, Compte rendu, Mississippi Gulf Coast, Risk, Sale, Low-Income Housing Tax Credit, GAAP, People's Bank, SEC, ASC, Annual report, Audit, Current, Materiality, Security (finance), Review

BILOXI, Miss., May 11, 2022 /PRNewswire/ -- Peoples Financial Corporation (the "Company")(OTCQX Best Market: PFBX), parent of The Peoples Bank, announced earnings for the first quarter ending March 31, 2022.

Key Points: 
  • BILOXI, Miss., May 11, 2022 /PRNewswire/ -- Peoples Financial Corporation (the "Company")(OTCQX Best Market: PFBX), parent of The Peoples Bank, announced earnings for the first quarter ending March 31, 2022.
  • Net income for the first quarter of 2022 was $887,000 compared to net income of $4,330,000 for the first quarter of 2021.
  • The earnings per weighted average common share for the first quarter of 2022 were $0.19 compared to earnings per weighted average common share of $0.89 for the first quarter of 2021.
  • Earnings for the first quarter of 2021 included a reduction in the allowance for loan losses of $4,853,000.

XBRL US Data Quality Committee Publishes 5 New Rules in 18th Draft Rule Set for US GAAP Filers

Retrieved on: 
Wednesday, April 20, 2022
Other Professional Services, Software, Finance, Banking, Data Management, Accounting, Professional Services, Technology, International Accounting Standards Board, EDGAR, GAAP, Adoption, Equity method, XBRL, U.S. Securities and Exchange Commission, Software, Center, EMI, Federal Energy Regulatory Commission, Single, Taxonomy, Finance, FASB, Review, IASB, Comment, Financial Accounting Standards Board, SEC, IFRS, Consolidated, Climate Disclosure Standards Board, Financial adviser, Security (finance), Audit, Risk management, Property management

The XBRL US Data Quality Committee (DQC) has published its 18th Rule Set for a 45-day public review and comment period, which closes on May 30, 2022.

Key Points: 
  • The XBRL US Data Quality Committee (DQC) has published its 18th Rule Set for a 45-day public review and comment period, which closes on May 30, 2022.
  • This latest draft rule set contains five rules specific to US GAAP filers:
    Equity Method Investment (EMI) Reporting.
  • The Financial Accounting Standards Board (FASB) maintains the Data Quality Committee Rules Taxonomy (DQCRT) which has incorporated 15 DQC rules into the FASB US GAAP Financial Reporting Taxonomy 2022 release.
  • http://xbrl.us
    Learn about the XBRL US Center for Data Quality: https://xbrl.us/cdq
    Find software that has been certified to run the rules: https://xbrl.us/certification
    View source version on businesswire.com: https://www.businesswire.com/news/home/20220419005704/en/